| Description | SP187 (MON-DNJ) is a host-targeted iminosugar. It has anti-filovirus infection activity.SP187 is used for therapeutic use against influenza and dengue viruses. |
| In vitro | SP187 (UV-4) is evaluated in vitro for its antiviral efficacy against EBOV and MARV using a yield-plaque assay format. SP187 demonstrates antiviral activity with IC50 values of 29.97 μM and 47.72 μM against EBOV and MARV, respectively.[1] |
| In vivo | In this study, C57Bl/6 mice are administered 10 or 100 mg/kg of SP187 or UV-5 via oral gavage or IP injection. Dosing started ~1h before infection with ~1000 pfu of mouse-adapted EBOV and is repeated BID for 10 days at approximately 12-hour intervals for UV-5 or TID at approximately 8-hour intervals for SP187. The selected doses and schedules are based on tolerability studies in naïve mice. No efficacy is observed in the iminosugar-treated mice as compared to the vehicle control.[1] |
| Target activity | MARV:47.72 μM, EBOV:29.97 μM |
| Synonyms | UV4, MON-DNJ |
| molecular weight | 319.44 |
| Molecular formula | C16H33NO5 |
| CAS | 615253-61-7 |
| Storage | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 63.89 mg/mL (200 mM) |
| References | 1. Warfield KL, et al. Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. Antiviral Res. 2017 Feb;138:22-31. |